Innate Pharma announces advancement of Sanofi-developed NK Cell Engager SAR443579/IPH6101 progressing to Phase 2 for blood cancer patients
Innate Pharma to hold its Annual General Meeting of shareholders on May 23, 2024
Innate Pharma presents at AACR 2024 preclinical efficacy of its pre-IND drug candidate IPH45, a novel Nectin-4 Antibody Drug Conjugate
Innate Pharma announces its participation in upcoming Investor Conference
Innate Pharma files its 2023 Universal Registration Document (Document d’enregistrement Universel) and 2023 Annual Report on Form 20-F
Innate Pharma reports Full Year 2023 financial results and business update
Innate Pharma announces its participation to upcoming investor conference
Innate Pharma announces conference call and webcast for Full Year 2023 financial results
Innate Pharma to present Nectin-4 Antibody Drug Conjugate IPH45 preclinical data at AACR 2024
First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin’s Lymphoma